Top-News

uniQure Aktie News

Aktie
WKN:  A1XDTV ISIN:  NL0010696654 US-Symbol:  QURE Branche:  Biotechnologie Land:  Niederlande
19,51 $
-0,24 $
-1,22%
16,618 € 12.12.25
Depot/Watchlist
Marktkapitalisierung *
923,10 Mio. €
Streubesitz
3,25%
KGV
-3,60
Index-Zuordnung
-

uniQure News

10.12.25 - PR Newswire
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm PR Newswire
04.12.25 - PR Newswire
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm PR Newswire
04.12.25 - GlobeNewswire
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies ...
28.11.25 - PR Newswire
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm PR Newswire
22.11.25 - PR Newswire
QURE Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
QURE Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm PR Newswire
20.11.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE PR Newswire
14.11.25 - PR Newswire
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE PR Newswire
11.11.25 - PR Newswire
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm PR Newswire
11.11.25 - PR Newswire
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE PR Newswire
10.11.25 - PR Newswire
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm PR Newswire
10.11.25 - GlobeNewswire
uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant ...
06.11.25 - GlobeNewswire
uniQure to Announce Third Quarter 2025 Financial Results
~ uniQure to host earnings call on Monday, November 10, 2025 at 8:30 a.m. ET ~
03.11.25 - GlobeNewswire
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies ...
28.10.25 - LYNX Analysen
uniQure weiter auf Erfolgskurs – Aktie bricht erneut nach oben aus
Die uniQure-​Aktie konnte zuletzt erneut zulegen und scheint ihren Aufwärtstrend fortzusetzen. Gelingt der nachhaltige Ausbruch über die jüngsten Widerstände? Jetzt vollständige ...
10.10.25 - ARIVA.DE Redaktion
Small-Cap-Biotech und UniQure: Die Gewinner der nächsten Biotech-Rallye!
Der Biotechnologiesektor boomt, mit Small-​Cap-Biotech als Treiber. Zinssenkungen und verstärkte M&A-​Aktivitäten bieten weiteres Potenzial, während Unternehmen wie UniQure ...
29.09.25 - GlobeNewswire
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies ...
26.09.25 - GlobeNewswire
uniQure Announces Pricing of Upsized $300 Million Public Offering
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies ...
25.09.25 - PR Newswire
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus PR Newswire
25.09.25 - PR Newswire
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus PR Newswire
25.09.25 - wallstreetONLINE Redaktion
Biotech-Aktie: UniQure explodiert: 265 Prozent an einem Tag!
Das niederländische Unternehmen UniQure meldet bahnbrechende Ergebnisse. Die Aktie des Biotech-​Unternehmens explodiert!UniQure gab am Mittwoch bekannt, dass seine ...

Newssuche

Videos

newspaper
12.12.25 +5,70%
Technical Trading: Neues Allzeithoch im Visier
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

Breaking News
ParaZero Technologies Ltd
1,09 €
-2,68%
ParaZero Technologies Ltd Chart
Parazero Technologies und die Bundespolizei!
Mehr zur Aktie »